Financing
Payment of Deferred Purchase Consideration
AbbVie Payment of Deferred Purchase Consideration increased by 102.9% to $2.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 97.0%, from $67.00M to $2.00M. Over 4 years (FY 2021 to FY 2025), Payment of Deferred Purchase Consideration shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2013
Last reportedQ1 2026May 8, 2026
Metric ID:
isrg_payment_of_deferred_purchase_considerationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $181.00M | $167.00M | $218.00M | $246.00M | $236.00M | $335.00M | $315.00M | $311.00M | $330.00M | $94.00M | $17.00M | $0.00 | $0.00 | $0.00 | $0.00 | $67.00M | -$35.00M | $37.00M | -$69.00M | $2.00M |
| QoQ Change | — | -7.7% | +30.5% | +12.8% | -4.1% | +41.9% | -6.0% | -1.3% | +6.1% | -71.5% | -81.9% | -100.0% | — | — | — | — | -152.2% | +205.7% | -286.5% | +102.9% |
| YoY Change | — | — | — | — | +30.4% | +100.6% | +44.5% | +26.4% | +39.8% | -71.9% | -94.6% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -97.0% |
Range-$69.00M – $335.00M
CAGR-61.3%
Avg YoY Growth-35.2%
Median YoY Growth-83.3%
Payment of Deferred Purchase Consideration at Other Companies
Frequently Asked Questions
- What is AbbVie's payment of deferred purchase consideration?
- AbbVie (ABBV) reported payment of deferred purchase consideration of $2.00M in Q1 2026.
- How has AbbVie's payment of deferred purchase consideration changed year-over-year?
- AbbVie's payment of deferred purchase consideration decreased by 97.0% year-over-year, from $67.00M to $2.00M.
- What is the long-term trend for AbbVie's payment of deferred purchase consideration?
- Over 4 years (2021 to 2025), AbbVie's payment of deferred purchase consideration has grown at a -100.0% compound annual growth rate (CAGR), from $698.00M to $0.00.